Thyrocare Technologies Limited — PPTs, 23-07-2026: Investor Presentation

Thyrocare delivered a robust Q1 FY27! Consolidated revenue surged 24% YoY to 240 Cr. Profit After Tax (PAT) jumped 34% YoY to 51.33 Cr, with EBITDA also up 34% YoY. Pathology, the core business, saw 26% growth, processing 55.2 Million tests (+28%) for 5.4 Million patients (+17%). Radiology revenue declined 4% due to exiting non-profitable centers.

The company is focusing on expanding its franchisee network and boosting specialty offerings like advanced pathology and genomic diagnostics. Recent highlights include new labs in Muzaffarpur, Prayagraj, and Kurnool, plus adding Gut Microbiome and Whole Exome Sequencing tech. Management aims to enhance patient value and reinforce market position through these strategic initiatives and partnerships.